Likewise, we have previously shown that CBL ameliorates the neurodegenerative pathology in amyloid precursor protein (APP) transgenic (tg) models of AD [12–15] as well as in models of tauopathy expressing 4R tau [16, 17]. The gene discussed is MAPT; the disease is Alzheimer disease.